Patent · US Active

Cancer treatment with epothilones

US7875601B2 · kind B2 · utility

4Cited by

22References

36Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Terence O'Reilly · Basel, CH
Markus Wartmann · Riehen, CH
Manuel Litchman · Teaneck, US
Pamela Cohen · Tenafly, US

Key dates

Filing date	Apr 19, 2006
Grant date	Jan 25, 2011
Priority date	—
Expiry date	Nov 25, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.